{"transactions":[{"id":4639438,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-10-13T20:24:28.000Z","date":"2026-10-10","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the RSUs vested and settled on each of October 10, 2024, October 10, 2025 and October 10, 2026. The remaining 25% of the shares will vest on 10/10/2027, provided that at the relevant vesting date the Reporting Person's employment relationship has not been terminated as defined in the Issuer's 2023 Employment Inducement Award Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"25% of the RSUs vested and settled on each of October 10, 2024, October 10, 2025 and October 10, 2026. The remaining 25% of the shares will vest on 10/10/2027, provided that at the relevant vesting date the Reporting Person's employment relationship has not been terminated as defined in the Issuer's 2023 Employment Inducement Award Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason."}],"balance_after":50000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001434647-26-000075","document":"wk-form4_1791923065.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1681098/000143464726000075/wk-form4_1791923065.xml","form_type":"4"}},{"id":4639437,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-10-13T20:24:28.000Z","date":"2026-10-12","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":11.2474,"value":224948.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Adoption date of referenced 10b5-1(c) plan is: 03-25-2026"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $11.07 to $11.36. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":417225,"source":{"system":"sec-edgar","filing":"0001434647-26-000075","document":"wk-form4_1791923065.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1681098/000143464726000075/wk-form4_1791923065.xml","form_type":"4"}},{"id":4639436,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-10-13T20:24:28.000Z","date":"2026-10-10","kind":"exercise","planned":true,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":437225,"source":{"system":"sec-edgar","filing":"0001434647-26-000075","document":"wk-form4_1791923065.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681098/000143464726000075/wk-form4_1791923065.xml","form_type":"4"}},{"id":911705,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-02-10T21:49:28.000Z","date":"2026-02-07","kind":"exercise","planned":true,"acquired":false,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One third of the restricted stock units vested and settled on February 7, 2026. The remaining two thirds of the shares will vest and settle in two equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"One third of the restricted stock units vested and settled on February 7, 2026. The remaining two thirds of the shares will vest and settle in two equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date."}],"balance_after":75000,"derivative":{"underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001681098-26-000004","document":"wk-form4_1770760165.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000168109826000004/wk-form4_1770760165.xml","form_type":"4"}},{"id":911704,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-10T21:49:28.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":14625,"price":8.5597,"value":125185.6125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Adoption date of referenced 10b5-1(c) plan is: 3/21/2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $8.39 to $8.67. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":387225,"source":{"system":"sec-edgar","filing":"0001681098-26-000004","document":"wk-form4_1770760165.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000168109826000004/wk-form4_1770760165.xml","form_type":"4"}},{"id":911703,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-10T21:49:28.000Z","date":"2026-02-07","kind":"exercise","planned":true,"acquired":true,"shares":37500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":401850,"source":{"system":"sec-edgar","filing":"0001681098-26-000004","document":"wk-form4_1770760165.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000168109826000004/wk-form4_1770760165.xml","form_type":"4"}},{"id":924814,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-02-02T22:18:52.000Z","date":"2026-01-31","kind":"exercise","planned":true,"acquired":false,"shares":233334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"One third of the restricted stock units vested and settled on each of January 31, 2025 and January 31, 2026. The remaining one third of the shares will vest and settle on January 31, 2027, subject to\nthe Reporting person's continued service through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"One third of the restricted stock units vested and settled on each of January 31, 2025 and January 31, 2026. The remaining one third of the shares will vest and settle on January 31, 2027, subject to\nthe Reporting person's continued service through such vesting date."}],"balance_after":233333,"derivative":{"underlying":"Common Stock","underlying_shares":233334},"source":{"system":"sec-edgar","filing":"0001681098-26-000002","document":"wk-form4_1770070730.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000168109826000002/wk-form4_1770070730.xml","form_type":"4"}},{"id":924813,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-02T22:18:52.000Z","date":"2026-01-29","kind":"grant","planned":true,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":250000,"derivative":{"exercise_price":8.86,"expiration_date":"2036-01-28","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001681098-26-000002","document":"wk-form4_1770070730.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000168109826000002/wk-form4_1770070730.xml","form_type":"4"}},{"id":924812,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-02-02T22:18:52.000Z","date":"2026-01-29","kind":"grant","planned":true,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date."}],"balance_after":125000,"derivative":{"underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001681098-26-000002","document":"wk-form4_1770070730.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000168109826000002/wk-form4_1770070730.xml","form_type":"4"}},{"id":924811,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-02T22:18:52.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":91000,"price":9.3783,"value":853425.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Adoption date of referenced 10b5-1(c) plan is: 03-21-2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $8.94 to $9.53. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":364350,"source":{"system":"sec-edgar","filing":"0001681098-26-000002","document":"wk-form4_1770070730.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000168109826000002/wk-form4_1770070730.xml","form_type":"4"}},{"id":924810,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-02T22:18:52.000Z","date":"2026-01-31","kind":"exercise","planned":true,"acquired":true,"shares":233334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":455350,"source":{"system":"sec-edgar","filing":"0001681098-26-000002","document":"wk-form4_1770070730.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000168109826000002/wk-form4_1770070730.xml","form_type":"4"}},{"id":1020219,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2025-10-10T23:17:35.000Z","date":"2025-10-10","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the RSUs vested and settled on each of October 10, 2024 and October 10, 2025. The remaining 50% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates the Reporting Person's employment relationship has not been terminated as defined in the Issuer's 2023 Employment Inducement Award Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"25% of the RSUs vested and settled on each of October 10, 2024 and October 10, 2025. The remaining 50% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates the Reporting Person's employment relationship has not been terminated as defined in the Issuer's 2023 Employment Inducement Award Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason."}],"balance_after":100000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001681098-25-000005","document":"wk-form4_1760138252.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000168109825000005/wk-form4_1760138252.xml","form_type":"4"}},{"id":1020218,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-10-10T23:17:35.000Z","date":"2025-10-10","kind":"sale","planned":true,"acquired":false,"shares":19500,"price":10.8158,"value":210908.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Adoption date of referenced 10b5-1(c) plan is: 03-21-2025."}],"balance_after":222016,"source":{"system":"sec-edgar","filing":"0001681098-25-000005","document":"wk-form4_1760138252.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000168109825000005/wk-form4_1760138252.xml","form_type":"4"}},{"id":1020217,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-10-10T23:17:35.000Z","date":"2025-10-10","kind":"exercise","planned":true,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":241516,"source":{"system":"sec-edgar","filing":"0001681098-25-000005","document":"wk-form4_1760138252.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000168109825000005/wk-form4_1760138252.xml","form_type":"4"}},{"id":1267157,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-14T22:54:04.000Z","date":"2025-02-14","kind":"sale","planned":true,"acquired":false,"shares":30544,"price":8.0527,"value":245961.6688,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Adoption date of referenced 10b5-1(c) plan is: 10-15-2024"}],"balance_after":191516,"source":{"system":"sec-edgar","filing":"0001437749-25-004067","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774925004067/rdgdoc.xml","form_type":"4"}},{"id":1267156,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-14T22:54:04.000Z","date":"2025-02-13","kind":"sale","planned":true,"acquired":false,"shares":61273,"price":7.8571,"value":481428.0883,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Adoption date of referenced 10b5-1(c) plan is: 10-15-2024"}],"balance_after":222060,"source":{"system":"sec-edgar","filing":"0001437749-25-004067","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774925004067/rdgdoc.xml","form_type":"4"}},{"id":1276396,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2025-02-10T22:37:17.000Z","date":"2025-02-07","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units will vest and settle as to one third of the restricted stock units on February 7, 2026, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's continued service through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units will vest and settle as to one third of the restricted stock units on February 7, 2026, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's continued service through such vesting date."}],"balance_after":112500,"derivative":{"underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001437749-25-003328","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774925003328/rdgdoc.xml","form_type":"4"}},{"id":1276395,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-10T22:37:17.000Z","date":"2025-02-07","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the \"Plan\"). The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant."}],"balance_after":225000,"derivative":{"exercise_price":7.77,"expiration_date":"2035-02-06","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001437749-25-003328","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774925003328/rdgdoc.xml","form_type":"4"}},{"id":1287250,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2025-02-03T22:19:31.000Z","date":"2025-01-31","kind":"exercise","planned":false,"acquired":false,"shares":233333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The first tranche of the restricted stock units vested and settled on January 31, 2025, and the remaining two tranches of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The first tranche of the restricted stock units vested and settled on January 31, 2025, and the remaining two tranches of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date."}],"balance_after":466667,"derivative":{"underlying":"Common Stock","underlying_shares":233333},"source":{"system":"sec-edgar","filing":"0001437749-25-002623","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774925002623/rdgdoc.xml","form_type":"4"}},{"id":1287249,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-03T22:19:31.000Z","date":"2025-01-31","kind":"exercise","planned":false,"acquired":true,"shares":233333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":283333,"source":{"system":"sec-edgar","filing":"0001437749-25-002623","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774925002623/rdgdoc.xml","form_type":"4"}},{"id":1514044,"issuer":{"id":5169,"kind":"organization","name":"COLLEGIUM PHARMACEUTICAL, INC"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-16T23:23:00.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":7693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the grant of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock."}],"balance_after":49365,"source":{"system":"sec-edgar","filing":"0001062993-24-010541","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267565/000106299324010541/form4.xml","form_type":"4"}},{"id":1661483,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2024-02-03T01:10:14.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. \t Grant to the Reporting Person of restricted stock units (\"RSU\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units will vest and settle as to one third of the restricted stock units on January 31, 2025, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's ongoing employment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units will vest and settle as to one third of the restricted stock units on January 31, 2025, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's ongoing employment."}],"balance_after":700000,"derivative":{"underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001437749-24-003022","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924003022/rdgdoc.xml","form_type":"4"}},{"id":1761769,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2023-10-11T20:33:22.000Z","date":"2023-10-10","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant to the Reporting Person of restricted stock units (\"RSU\") under the Issuer's 2023 Employment Inducement Award Plan (the \"Plan\"). 25% of the shares will vest on October 10, 2024 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Grant to the Reporting Person of restricted stock units (\"RSU\") under the Issuer's 2023 Employment Inducement Award Plan (the \"Plan\"). 25% of the shares will vest on October 10, 2024 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason."}],"balance_after":200000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001437749-23-028052","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923028052/rdgdoc.xml","form_type":"4"}},{"id":1761768,"issuer":{"id":5212,"kind":"organization","name":"ZEVRA THERAPEUTICS, INC.","symbol":"ZVRA"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-10-11T20:33:22.000Z","date":"2023-10-10","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Grant to the Reporting Person of a stock option under the Issuer's 2023 Employment Inducement Award Plan (the \"Plan\"). 25% of the shares will vest on October 10, 2024 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant."}],"balance_after":600000,"derivative":{"exercise_price":4.75,"expiration_date":"2033-10-09","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001437749-23-028052","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923028052/rdgdoc.xml","form_type":"4"}},{"id":1884328,"issuer":{"id":5169,"kind":"organization","name":"COLLEGIUM PHARMACEUTICAL, INC"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-19T20:40:17.000Z","date":"2023-05-18","kind":"grant","planned":false,"acquired":true,"shares":9792,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 18, 2024, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock."}],"balance_after":41672,"source":{"system":"sec-edgar","filing":"0001062993-23-011820","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267565/000106299323011820/form4.xml","form_type":"4"}},{"id":2259746,"issuer":{"id":5169,"kind":"organization","name":"COLLEGIUM PHARMACEUTICAL, INC"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-23T20:44:24.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":14035,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 19, 2023, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock."}],"balance_after":31880,"source":{"system":"sec-edgar","filing":"0001062993-22-013303","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267565/000106299322013303/form4.xml","form_type":"4"}},{"id":2300138,"issuer":{"id":5169,"kind":"organization","name":"COLLEGIUM PHARMACEUTICAL, INC"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-08T21:12:30.000Z","date":"2022-04-06","kind":"grant","acquired":true,"shares":17845,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on April 6, 2023, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock."}],"balance_after":17845,"source":{"system":"sec-edgar","filing":"0001062993-22-010000","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267565/000106299322010000/form4.xml","form_type":"4"}},{"id":2494943,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-24T16:10:40.000Z","date":"2021-11-24","kind":"disposition_to_issuer","acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"$6.11 plus two CVRs per share underlying the stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Option shares shall vest as follows: 25% of the shares subject to the option shall vest on September 16, 2020 and an additional 1/48th of the shares subject to the option shall vest on a monthly basis thereafter over the following 36 months."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":1.99,"expiration_date":"2030-03-17","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001328143-21-000093","document":"wf-form4_163778822454298.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000132814321000093/wf-form4_163778822454298.xml","form_type":"4"}},{"id":2494942,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-24T16:10:40.000Z","date":"2021-11-24","kind":"disposition_to_issuer","acquired":false,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"$1.85 plus two CVRs per share underlying the stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Option shares shall vest as follows: 25% of the shares subject to the option shall vest on September 16, 2020 and an additional 1/48th of the shares subject to the option shall vest on a monthly basis thereafter over the following 36 months."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":6.25,"expiration_date":"2029-09-15","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001328143-21-000093","document":"wf-form4_163778822454298.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000132814321000093/wf-form4_163778822454298.xml","form_type":"4"}},{"id":2494941,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-24T16:10:40.000Z","date":"2021-11-24","kind":"other","acquired":false,"shares":600000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. (\"Parent\") and Supernus Reef, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 24, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights (\"CVRs\" and, collectively with the cash amount, the \"Per Share Price\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"A portion of this amount consists of unvested restricted stock units, including PRSUs (\"RSUs\"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001328143-21-000093","document":"wf-form4_163778822454298.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000132814321000093/wf-form4_163778822454298.xml","form_type":"4"}},{"id":2494940,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-24T16:10:40.000Z","date":"2021-11-24","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of performance-based restricted stock units (\"PRSUs\") granted to the reporting person on March 2, 2021. The performance conditions associated with the PRSUs had not yet occurred. Pursuant to the Merger Agreement (as defined below), immediately prior to the effective time of the Merger (as defined below), the PRSU was deemed to have vested."}],"balance_after":600000,"source":{"system":"sec-edgar","filing":"0001328143-21-000093","document":"wf-form4_163778822454298.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000132814321000093/wf-form4_163778822454298.xml","form_type":"4"}},{"id":2812078,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-03-03T17:01:32.000Z","date":"2021-03-02","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 1/3rd of the total number of Restricted Stock Units will vest on each of March 1, 2022, March 1, 2023 and March 1, 2024, subject to Reporting Person's Continuous Service as of each such date."}],"balance_after":525000,"source":{"system":"sec-edgar","filing":"0001209191-21-016973","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919121016973/doc4.xml","form_type":"4"}},{"id":3199080,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-20T18:07:29.000Z","date":"2020-03-18","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option shares shall vest as follows: 25% of the shares subject to the option shall vest on September 16, 2020 and an additional 1/48th of the shares subject to the option shall vest on a monthly basis thereafter over the following 36 months."}],"balance_after":200000,"derivative":{"exercise_price":1.99,"expiration_date":"2030-03-17","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-20-020527","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919120020527/doc4.xml","form_type":"4"}},{"id":3199079,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-03-20T18:07:29.000Z","date":"2020-03-18","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on each of September 16, 2020, September 16, 2021, September 16, 2022 and September 16, 2023, subject to Reporting Person's Continuous Service as of each such date."}],"balance_after":225000,"source":{"system":"sec-edgar","filing":"0001209191-20-020527","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919120020527/doc4.xml","form_type":"4"}},{"id":3411909,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-17T19:00:39.000Z","date":"2019-09-16","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option shares shall vest as follows: 25% of the shares subject to the option shall vest on September 16, 2020 and an additional 1/48th of the shares subject to the option shall vest on a monthly basis thereafter over the following 36 months."}],"balance_after":250000,"derivative":{"exercise_price":6.25,"expiration_date":"2029-09-15","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-19-049941","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919119049941/doc4.xml","form_type":"4"}},{"id":3411908,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-09-17T19:00:39.000Z","date":"2019-09-16","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on each of September 16, 2020, September 16, 2021, September 16, 2022 and September 16, 2023, subject to Reporting Person's Continuous Service as of each such date."}],"balance_after":125000,"source":{"system":"sec-edgar","filing":"0001209191-19-049941","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919119049941/doc4.xml","form_type":"4"}},{"id":3523739,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2019-05-17T01:37:52.000Z","date":"2019-05-16","kind":"sale","acquired":false,"shares":984,"price":18.71,"value":18410.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."}],"balance_after":26988,"source":{"system":"sec-edgar","filing":"0001209191-19-030661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119030661/doc4.xml","form_type":"4"}},{"id":3523738,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2019-05-17T01:37:52.000Z","date":"2019-05-15","kind":"sale","acquired":false,"shares":984,"price":17.78,"value":17495.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.67 to $17.86,\ninclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":27972,"source":{"system":"sec-edgar","filing":"0001209191-19-030661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119030661/doc4.xml","form_type":"4"}},{"id":3721250,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-12-22T01:21:21.000Z","date":"2018-12-20","kind":"sale","acquired":false,"shares":6404,"price":22.5565,"value":144451.826,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.24 to $23.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":28956,"source":{"system":"sec-edgar","filing":"0001209191-18-064023","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118064023/doc4.xml","form_type":"4"}},{"id":3721249,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-12-22T01:21:21.000Z","date":"2018-12-20","kind":"sale","acquired":false,"shares":4721,"price":22.0041,"value":103881.3561,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.76 to $22.23,\ninclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":35360,"source":{"system":"sec-edgar","filing":"0001209191-18-064023","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118064023/doc4.xml","form_type":"4"}},{"id":3723283,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-12-21T00:57:37.000Z","date":"2018-12-18","kind":"grant","acquired":true,"shares":11125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2017, the reporting person was granted performance restricted stock units (PRSUs) covering 22,250 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On December 18, 2018, a portion of the PRSUs vested upon the Issuer's confirmation that the Phase 3 FORT study of fosmetpantotenate in PKAN had fully enrolled."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 480 shares of the Issuer's common stock acquired by the reporting person on November 30, 2018 pursuant to an employee stock purchase program."}],"balance_after":40081,"source":{"system":"sec-edgar","filing":"0001209191-18-063774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118063774/doc4.xml","form_type":"4"}},{"id":3760843,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-11-17T00:19:13.000Z","date":"2018-11-14","kind":"sale","acquired":false,"shares":1000,"price":24.6435,"value":24643.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.38 to $24.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":28476,"source":{"system":"sec-edgar","filing":"0001209191-18-059067","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118059067/doc4.xml","form_type":"4"}},{"id":3760842,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-11-17T00:19:13.000Z","date":"2018-11-14","kind":"sale","acquired":false,"shares":9000,"price":23.6301,"value":212670.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.35 to $24.34,\ninclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":29476,"source":{"system":"sec-edgar","filing":"0001209191-18-059067","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118059067/doc4.xml","form_type":"4"}},{"id":3764530,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-11-15T01:44:19.000Z","date":"2018-11-09","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 15, 2016, the reporting person was granted performance restricted stock units (PRSUs) covering 30,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria.  On November 9, 2018, a portion of the PRSUs vested upon the Issuer's confirmation that the US Food and Drug Administration had accepted for review a New Drug Application filed by the Issuer's partner."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 528 shares of the Issuer's common stock acquired by the reporting person on May 31, 2018 pursuant to an employee stock purchase program."}],"balance_after":38476,"source":{"system":"sec-edgar","filing":"0001209191-18-058649","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118058649/doc4.xml","form_type":"4"}},{"id":3934669,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Performance-based restricted stock units","published_at":"2018-05-14T23:33:38.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 10, 2022 to the extent the specified clinical and regulatory milestones are not achieved by such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 10, 2022 to the extent the specified clinical and regulatory milestones are not achieved by such date."}],"balance_after":10500,"derivative":{"underlying":"Common Stock","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0001209191-18-030057","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118030057/doc4.xml","form_type":"4"}},{"id":3934668,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2018-05-14T23:33:38.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":63000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":63000,"derivative":{"exercise_price":25.25,"expiration_date":"2028-05-09","underlying":"Common Stock","underlying_shares":63000},"source":{"system":"sec-edgar","filing":"0001209191-18-030057","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118030057/doc4.xml","form_type":"4"}},{"id":3934667,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-05-14T23:33:38.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":27948,"source":{"system":"sec-edgar","filing":"0001209191-18-030057","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118030057/doc4.xml","form_type":"4"}},{"id":4066049,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2018-02-13T01:38:40.000Z","date":"2018-02-08","kind":"grant","acquired":true,"shares":2546,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,280 ordinary shares of the Issuer acquired by the reporting person on November 30, 2017 pursuant to an employee stock purchase program."}],"balance_after":17448,"source":{"system":"sec-edgar","filing":"0001209191-18-009398","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118009398/doc4.xml","form_type":"4"}},{"id":4230665,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2017-08-18T00:36:39.000Z","date":"2017-08-16","kind":"sale","acquired":false,"shares":1378,"price":22.5,"value":31005.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold to cover the tax obligation that occurred upon the vesting of an RSU."}],"balance_after":13622,"source":{"system":"sec-edgar","filing":"0001209191-17-049546","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919117049546/doc4.xml","form_type":"4"}},{"id":4313489,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":67035,"kind":"person","name":"McFarlane Neil F.","position":1,"cik":"0001681098","reported_name":"McFarlane Neil F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2017-05-18T22:15:06.000Z","date":"2017-05-17","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in sixteen equal quarterly installments from the date of grant."}],"balance_after":90000,"derivative":{"exercise_price":17.44,"expiration_date":"2027-05-16","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-17-033718","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919117033718/doc4.xml","form_type":"4"}}]}